The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.
MDC Connects 2021: A Guide to Complex Medicines is a series of webinars exploring the opportunities and challenges presented by this new class of medicines, and takes you through the steps to take an idea from concept to the clinic.
In this session, we will look at assays, technologies and capabilities which can be employed to characterise the lead molecule.
Developing the assay cascade for complex medicines – Tilly Bingham (Concept Life Sciences)
Cellular internalisation and trafficking of complex medicines – Dr Jamie Szczerkowski (MDC)
CryoEM in characterisation and quality control of complex medicines – Rebecca Thompson (Astbury Biostructure Laboratory)
Developing the assay cascade for complex medicines
Cellular internalisation and trafficking of complex medicines
CryoEM in characterisation and quality control of complex medicines